Bmi-1 was also found to be a negative prognostic factor in gastric cancer and endometrial adenocarcinoma, each demonstrating heightened Bmi-1 expression to be indicative of worse clinical stage, lymph node metastases, and overall survival (116, 117). This evidence concerns the gene BMI1 and metastatic malignant neoplasm in the lymph nodes.